| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 8.7 | % |
| Activity | = | 2 | % |
| Activity | = | 1.5 | % |
| Activity | = | 5.7 | % |
| Activity | = | 4.1 | % |
| Activity | = | 2 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 10.1 | % |
| Activity | = | 11.7 | % |
| Activity | = | 7.1 | % |
| Activity | = | 5.8 | % |
| Activity | = | 4.3 | % |
| Activity | = | 1.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 41.5 | % |
| Activity | = | 89.8 | % |
| Activity | = | 88.9 | % |
| Activity | = | 48 | % |
| Activity | = | 41.6 | % |
| Activity | = | 60.8 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 44.6 | % |
| Activity | = | 74.9 | % |
| Activity | = | 61.6 | % |
| Activity | = | 54.7 | % |
| Activity | = | 27.8 | % |
| Activity | = | 74.4 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 10 | Ki | > | 10000 | nM | |
| 0.54 | Ki | = | 540 | nM | |
| 20 | Ki | > | 20000 | nM | |
| 20 | Ki | > | 20000 | nM | |
| 20 | Ki | > | 20000 | nM | |
| 22.48 | Ki | = | 22480 | nM | |
| 17.58 | IC50 | = | 17580 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 12.4 | % |
| Activity | = | 21 | % |
| Activity | = | 59.3 | % |
| Activity | = | 33.4 | % |
| Activity | = | 18.6 | % |
| Activity | = | 16.5 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 28.2 | % |
| Activity | = | 54.2 | % |
| Activity | = | 52.9 | % |
| Activity | = | 40.3 | % |
| Activity | = | 12.2 | % |
| Activity | = | 27.4 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 29.1 | % |
| Activity | = | 68.8 | % |
| Activity | = | 29.6 | % |
| Activity | = | 14.6 | % |
| Activity | = | 23 | % |
| Activity | = | 44.3 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 16.4 | % |
| Activity | = | 20.8 | % |
| Activity | = | 8.7 | % |
| Activity | = | 14.4 | % |
| Activity | = | 15.6 | % |
| Activity | = | 47 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 44.9 | % |
| Activity | = | 10.9 | % |
| Activity | = | 31.4 | % |
| Activity | = | 39.5 | % |
| Activity | = | 67.9 | % |
| Activity | = | 24.3 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 39.6 | IC50 | = | 39600 | nM | |
| 64.7 | IC50 | = | 64700 | nM | |
| 29.9 | IC50 | = | 29900 | nM | |
| 106.6 | IC50 | = | 106600 | nM | Outside typical range |
| 73.2 | IC50 | = | 73200 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 10 | Ki | > | 10000 | nM | |
| 9.37 | Ki | = | 9370 | nM | |
| 16.56 | IC50 | = | 16560 | nM | |
| 18.11 | Ki | = | 18110 | nM | |
| 34.15 | IC50 | = | 34150 | nM | |
| 20 | Ki | > | 20000 | nM | |
| Ki | ND(Insoluble) |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 49.8 | % |
| Activity | = | 8.3 | % |
| Activity | = | 9.7 | % |
| Activity | = | 46.3 | % |
| Activity | = | 54.3 | % |
| Activity | = | 37.2 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 13.7 | EC50 | = | 13700 | nM |
| 23.1 | EC50 | = | 23100 | nM |
| 1.5 | EC50 | = | 1500 | nM |
| 2.1 | EC50 | = | 2100 | nM |
| 13.8 | EC50 | = | 13800 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 80 | % |
| Activity | = | 100 | % |
| Activity | = | 71.5 | % |
| Activity | = | 0 | % |
| Activity | = | 30 | % |
| Activity | = | 65.6 | % |
| Activity | = | 0 | % |
| Activity | = | 19.3 | % |
| Activity | = | 81.8 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 36.4 | % |
| Activity | = | 29.5 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 80 | % |
| Activity | > | 80 | % |
| Activity | = | 100 | % |
| Activity | = | 70 | % |
| Activity | > | 80 | % |
| Activity | = | 100 | % |
| Activity | = | 70 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 80 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | > | 80 | % |
| Activity | = | 100 | % |
| Activity | > | 80 | % |
| Activity | = | 80 | % |
| Activity | = | 60 | % |
| Activity | = | 80 | % |
| Activity | = | 0 | % |
| Activity | = | 50 | % |
| Activity | = | 80 | % |
| Activity | = | 20 | % |
| Activity | = | 20 | % |
| Activity | = | 80 | % |
| Activity | = | 50 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 4.9 | EC50 | = | 4900 | nM |
| 21.3 | EC50 | = | 21300 | nM |
| 30 | EC50 | > | 30000 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 4.9 | EC50 | = | 4900 | nM |
| 30 | EC50 | > | 30000 | nM |
| 30 | EC50 | > | 30000 | nM |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 55.1 | % |
| Activity | = | 80 | % |
| Activity | = | 100 | % |
| Activity | = | 65.6 | % |
| Activity | = | 71.7 | % |
| Activity | = | 100 | % |
| Activity | = | 59.6 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Activity | = | 46.3 | % |
| Activity | = | 100 | % |
| Activity | = | 100 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 20 | % |
| Activity | = | 80 | % |
| Activity | = | 80 | % |
| Activity | = | 80 | % |
| Activity | = | 20 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 10 | % |
| Activity | = | 60 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 50 | % |
| Activity | = | 0 | % |
| Activity | = | 50 | % |
| Activity | = | 40 | % |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | = | 0 | % |
| Activity | = | 1.6 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 2.3 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 1.6 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| Activity | = | 0 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.5 | EC50 | = | 5500 | nM |
| 30 | EC50 | > | 30000 | nM |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 5.9 | EC50 | = | 5900 | nM |
| 19.3 | EC50 | = | 19300 | nM |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 5.5 | EC50 | = | 5500 | nM | |
| 30 | EC50 | > | 30000 | nM | |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 7.9 | EC50 | = | 7900 | nM |
| 30 | EC50 | > | 30000 | nM |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| EC50 | Not Determined | ||||
| EC50 | Not Determined | ||||
| EC50 | Not Determined |
| Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| Activity | < | 10 | % |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 6.7 | EC50 | = | 6700 | nM | |
| EC50 | Not Determined | ||||
| 5.1 | EC50 | = | 5100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| EC50 | Not Determined | ||||
| 12.7 | EC50 | = | 12700 | nM | |
| 11.1 | EC50 | = | 11100 | nM |
| Species | Strain | IsPseudotypeVirus | AssayMeth | Target | Mutations | IC50Mod | IC50 | IC50Unit | ICOtherPct | ICOtherPctUnit | ICOtherConc | ICOtherConcUnit | KiMod | Ki | KiUnit | Km | KmUnit | HostAnalog | HostAnalogSpecies | RelResFoldChgMod | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| 3' PROCESSING | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18662877 | EFFICIENT SYNTHESIS AND UTILIZATION OF PHENYL-SUBSTITUTED HETEROAROMATIC CARBOXYLIC ACIDS AS ARYL DIKETO ACID ISOSTERES IN THE DESIGN OF NOVEL HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2008, 18(16), 4521-4. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 6.2 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5.3 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | dTTP incorporation assay by liquid scintillation | Reverse transcriptase | 5 | uM | 19442130 | CHARACTERIZATION OF HIV-1 ENZYME REVERSE TRANSCRIPTASE INHIBITION BY THE COMPOUND 6-CHLORO-1,4-DIHYDRO-4-OXO-1-(BETA-D-RIBOFURANOSYL) QUINOLINE-3-CARBOXYLIC ACID THROUGH KINETIC AND IN SILICO STUDIES. Current HIV Research 2009, 7(3), 327-335. | |||||||||||||||||||
| HIV-1 | N | standard reverse transcriptase assay | Reverse transcriptase | 50 | ug/mL | SYNTHESIS AND HIV-1 REVERSE TRANSCRIPTASE INHIBITION ACTIVITY OF 1,4-NAPHTHOQUINONE DERIVATIVES. Chemistry of Natural Compounds 2012, 47(6), 883-887. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| STRAND TRANSFER | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| 3'-PROCESSING | Integrase | > | 100 | uM | 18805696 | DISCOVERY OF 3-ACETYL-4-HYDROXY-2-PYRANONE DERIVATIVES AND THEIR DIFLUORIDOBORATE COMPLEXES AS A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry 2008, 16(19), 8988-98. | |||||||||||||||||||
| HIV-1 | STRAND TRANSFER | Integrase | 0.015 | uM | 19523819 | N-(4-FLUOROBENZYL)-3-HYDROXY-9;9-DIMETHYL-4-OXO-6;7;8;9-TETRAHYDRO-4H-PYRAZINO[1;2-A]PYRIMIDINE-2-CARBOXAMIDES A NOVEL CLASS OF POTENT HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2009, 19, 4245-9. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 5.8 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 170.3 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 10.2 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ASSAY | Reverse transcriptase | 33.7 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | HPLC | Protease | 24.9 | uM | 18543149 | INHIBITION OF HIV-1 PROTEASE AND RNASE H OF HIV-1 REVERSE TRANSCRIPTASE ACTIVITIES BY LONG CHAIN PHENOLS FROM THE SARCOTESTAS OF GINKGO BILOBA. Planta Medica 2008, 74(5), 532-534. | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | Strand Transfer | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . | |||||||||||||||||||
| HIV-1 | 3'-processing | Integrase | > | 100 | uM | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS. . Patent 2009, , . |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 10.1 | EC50 | = | 10100 | nM | |
| 10.3 | EC50 | = | 10300 | nM | |
| 7.1 | EC50 | = | 7100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 9.8 | EC50 | = | 9800 | nM | |
| 9.1 | EC50 | = | 9100 | nM | |
| 6.1 | EC50 | = | 6100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 6 | EC50 | = | 6000 | nM | |
| 6.4 | EC50 | = | 6400 | nM | |
| 6.2 | EC50 | = | 6200 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 6.6 | EC50 | = | 6600 | nM | |
| 9 | EC50 | = | 9000 | nM | |
| 9.7 | EC50 | = | 9700 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 12.6 | EC50 | = | 12600 | nM |
| 11.2 | EC50 | = | 11200 | nM |
| 8.1 | EC50 | = | 8100 | nM |
| Species | Strain | IsPseudotypeVirus | AssayMeth | CellType | CellType2 | Target | Mutations | EC50Mod | EC50 | EC50Unit | ECOtherPct | ECOtherPctUnit | ECOtherConc | ECOtherConcUnit | ToxAssayMeth | ToxCellType | CC50Mod | CC50 | CC50Unit | TIMod | TI | RelResFoldChg | Comments | Reference | Citation | Other Information |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-1 | LAI | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 76.74 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| HIV-1 | MN | RT | HuT TK+ | HuT 78 | Reverse transcriptase | < | 0.3 | uM | 69 | % | 0.3 | uM | MTT | > | 10 | uM | > | 33.3 | HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. | |||||
| R5; CLINICAL ISOLATE | 1(JSL) | P24 | PBMC | Reverse transcriptase | MDR | 0.07 | uM | 90 | % | 1 | uM | MTT | > | 100 | uM | > | 1428 | HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN | 15280474 | SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662. | ECOtherConcMod:> | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | NL4-3 | LUCIFERASE | 1G5 T | Reverse transcriptase | < | 1 | uM | 99 | % | 1 | uM | TRYPAN BLUE | > | 1 | uM | > | 1 | ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION | 16725040 | INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP. | CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM | |||||
| HIV-1 | LAV | RT | U1(THF-.alpha. STIM) | U1 | Tumor necrosis factor alpha | ~ | 30 | ug/mL | 70 | % | 50 | ug/mL | > | 50 | ug/mL | > | 1.66 | CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE | 8327469 | THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 75 | % | 10 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 38 | % | 2 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | BaL | P24 (DAY 18) | MACROPHAGES(GM-CSF) | Macrophage | Ribonucleotide reductase | < | 10 | uM | 99 | % | 50 | uM | > | 1000 | uM | > | 10 | MAXIMAL P24 EXPRESSION AT DAY 18 | 7973634 | HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805. | ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM | |||||
| HIV-1 | IIIB | RT | HT4(R116; AZT RESISTANT CELLS) | HT4 | Reverse transcriptase | ~ | 0.01 | uM | 70 | % | 0.01 | uM | ~` | 1 | uM | ~ | 100 | FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES | 8827211 | USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968. | ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.1 | uM | 52 | % | 0.1 | uM | TRYPAN BLUE | > | 100 | uM | > | 1000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 78 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | IIIB | SYNCYT FORM | MOLT-4/H9(HIV-1(IIIB)) | MOLT-4 | gp120 | < | 1 | uM | 95 | % | 10 | uM | -100 | 10 | uM | > | 10 | CHRONICALLY INFECTED H9 CELLS | 9343823 | TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724. | CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM | |||||
| HIV-1 | 1 | .beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATION | HeLa H12(HIV-1 LTR-Laz, TAT) | HeLa | Tat:TAR/LTR | < | 0.01 | uM | 75 | % | 0.01 | uM | TRYPAN BLUE | > | 100 | uM | > | 10000 | DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION | 9561563 | CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52. | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.25 | uM | 95 | % | 0.25 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 80 | IN THE PRESENCE OF 50% NHS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | 1 | P24 | MT-4 | Integrase | < | 0.103 | uM | 95 | % | 0.103 | uM | MICROSCOPIC EXAMINATION | > | 20 | uM | > | 194 | IN THE PRESENCE OF 10% FBS | 16554152 | A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904. | ECOtherPctMod:> | |||||
| HIV-1 | NL4-3 | RT | MT-4 | Reverse transcriptase | < | 1 | uM | 100 | % | 1 | uM | WST-8 | > | 1 | uM | > | 1 | MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION | 15371436 | POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063. | ||||||
| HIV-1 | LAI | RT | HuT 78 | Reverse transcriptase | < | 1 | uM | 57.14 | % | 1 | uM | MTT | > | 10 | uM | > | 10 | MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID50 | 9281520 | USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405. |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 11.8 | EC50 | = | 11800 | nM | |
| 15.5 | EC50 | = | 15500 | nM | |
| 12.1 | EC50 | = | 12100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 16.9824 | IC50 | = | 16982.44 | nM | |
| 14.1254 | IC50 | = | 14125.38 | nM | |
| 14 | IC50 | = | 14000 | nM | |
| 8.91251 | IC50 | = | 8912.51 | nM | |
| 9 | IC50 | = | 9000 | nM | |
| 19.0546 | IC50 | = | 19054.61 | nM | |
| 19 | IC50 | = | 19000 | nM | |
| 66 | IC50 | = | 66000 | nM | |
| 50 | IC50 | = | 50000 | nM | |
| 66 | IC50 | = | 66000 | nM | |
| 7 | IC50 | = | 7000 | nM | |
| 151.356 | IC50 | = | 151356.12 | nM | Outside typical range |
| 30.1995 | IC50 | = | 30199.52 | nM | |
| 31 | IC50 | = | 31000 | nM | |
| 162.181 | IC50 | = | 162181.01 | nM | Outside typical range |
| 31.8 | IC50 | = | 31800 | nM | |
| 31.6228 | IC50 | = | 31622.78 | nM | |
| 41.2 | IC50 | = | 41200 | nM | |
| 7.24436 | IC50 | = | 7244.36 | nM | |
| 107.9 | IC50 | = | 107900 | nM | Outside typical range |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| EC50 | Not Determined | ||||
| 17.8 | EC50 | = | 17800 | nM | |
| 3.1 | EC50 | = | 3100 | nM | |
| 2.8 | EC50 | = | 2800 | nM | |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 28.8 | EC50 | = | 28800 | nM |
| 25.5 | EC50 | = | 25500 | nM |
| 4.7 | EC50 | = | 4700 | nM |
| 4.3 | EC50 | = | 4300 | nM |
| 18.8 | EC50 | = | 18800 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 37.2 | EC50 | = | 37200 | nM |
| 16.6 | EC50 | = | 16600 | nM |
| 7.7 | EC50 | = | 7700 | nM |
| 2 | EC50 | = | 2000 | nM |
| 15.1 | EC50 | = | 15100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units |
|---|---|---|---|---|
| 23.4 | EC50 | = | 23400 | nM |
| 18.9 | EC50 | = | 18900 | nM |
| 2.5 | EC50 | = | 2500 | nM |
| 6.5 | EC50 | = | 6500 | nM |
| 29.1 | EC50 | = | 29100 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| 19.5 | EC50 | = | 19500 | nM | |
| 10.5 | EC50 | = | 10500 | nM | |
| 0.5 | EC50 | = | 500 | nM | |
| EC50 | Not Determined | ||||
| 7.2 | EC50 | = | 7200 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Activity Comment |
|---|---|---|---|---|---|
| EC50 | Not Determined | ||||
| EC50 | Not Determined | ||||
| EC50 | Not Determined | ||||
| 3.3 | EC50 | = | 3300 | nM | |
| 30 | EC50 | > | 30000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 21.1 | EC50 | = | 21100 | nM | |
| 12.2 | EC50 | = | 12200 | nM | |
| 33.8 | EC50 | = | 33800 | nM | |
| 1.6 | EC50 | = | 1600 | nM | |
| 8 | EC50 | = | 8000 | nM |
| PubChem Standard Value | Standard Type | Standard Relation | Standard Value | Standard Units | Data Validity Comment |
|---|---|---|---|---|---|
| 50.16 | IC50 | = | 50160 | nM | |
| 38.73 | IC50 | = | 38730 | nM | |
| 0.22 | IC50 | = | 220 | nM | |
| 84.07 | IC50 | = | 84070 | nM | |
| 68.69 | IC50 | = | 68690 | nM |